Puma Biotechnology (PBYI) Cash from Financing Activities (2010 - 2026)

Puma Biotechnology (PBYI) has 15 years of Cash from Financing Activities data on file, last reported at -$11.3 million in Q1 2026.

• Quarterly Cash from Financing Activities changed 0.0% year-over-year to -$11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.2 million (changed 0.04% YoY) and the FY2025 annual result came in at -$45.2 million, down 33.54% from the prior year.
• Cash from Financing Activities steadied at -$11.3 million in Q1 2026, from -$11.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $9.8 million in Q1 2022 to a low of -$11.3 million in Q2 2024.
• A 4-year average of -$7.1 million and a median of -$11.3 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 121650.0% — and 2025, when it dropped 1.33%.
• Tracing PBYI's Cash from Financing Activities over 4 years: stood at $2.4 million in 2022, then tumbled by 566.1% to -$11.3 million in 2024, then slipped by 0.01% to -$11.3 million in 2025, then changed by 0.0% to -$11.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$11.3 million (Q1 2026), -$11.3 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.